ADULT UROLOGY ROLE OF THE NITRIC OXIDE DONOR LINSIDOMINE CHLORHYDRATE (SIN-l) IN THE DIAGNOSIS AND TREATMENT OF ERECTILE DYSFUNCTION*

ABSTRACT--Objectives. Recently, nitric oxide was shown to be a mediator of penile erection in men and the nitric oxide donor linsidomine chlorhydrate (StN-1) was intro-duced as a novel treatment option i patients with erectile dysfunction. We now present our follow-up results with the intracavernous application of SIN-1. Methods. One hundred thirteen patients with erectile dysfunction of various etiologies and 10 normal control subjects underwent intracavernous pharmacotesting with 1 mg SIN-1. Of the 113 patients, 71 (62.8%) underwent additional pharmacotesting with a mixture of papaverine (15 mg/mL) and phentolamine (0.5 mg/mL) (P/P). Forty-eight re-sponders to SIN-1 were enrolled in an autoinjection program with this substance. Results. All normal control subjects had full rigid erections lasting 40 to 70 minutes. Of 113 patients, 78 (69%) had responses sufficient for intercourse with SIN-l, and the other 35 patients (31%) demonstrated inadequate responses. All 44 responders to SIN-1 who also received P/P had erections sufficient for intercourse with P/P in doses of 0.25 to 2 mL (mean, 0.6 + 0.3 mL). Six patients (13.6%) had prolonged erections with minimal to moderate doses of P/P. From the total of 27 patients who had erections insufficient fo